Physician profile
Marta E Banegas
NPI 1477542926
$1,877.16
in general payments reported to CMS, 2019-2025
22 companies · $60.33 in 2025
The $60.33 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $90.91 · 2021: $386 · 2022: $457 · 2023: $243 · 2024: $214 · 2025: $60.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $375.21 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $227.47 | 2019-2022 | |
| Abbvie INC. | $224.71 | 2021-2023 | Vraylar |
| Alkermes, INC. | $140.95 | 2021-2023 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $136.07 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $130.98 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $84.74 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.31 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $73.12 | 2021-2022 | |
| Axsome Therapeutics, INC. | $50.60 | 2023-2024 | Auvelity |
| Adlon Therapeutics L.P. | $48.35 | 2019-2020 | |
| Lundbeck LLC | $45.80 | 2020-2023 | Abilify Maintena |
| Allergan, INC. | $37.85 | 2020 | |
| Neos Therapeutics, LP | $36.04 | 2019 | |
| Almatica Pharma LLC | $33.01 | 2022-2024 | Loreev Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $29.26 | 2024 | |
| Corium, LLC | $27.42 | 2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $26.73 | 2022 | |
| Bausch Health US, LLC | $20.43 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.22 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.51 | 2019 | |
| Shire North American Group INC | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Banegas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.